14 February 2018

Notice of Interim Results


genedrive plc, (AIM: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ending 31 December 2017 on Tuesday 20 March.


David Budd, Chief Executive Officer, and Matthew Fowler, Chief Financial Officer, will host a presentation and simultaneous live conference call for analysts, followed by a Q&A session, at 9:30am on the day of the results. The presentation will be held at 85 Gresham Street, London, EC2R 7HE.


-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                     +44 (0)161 989 0245

Matthew Fowler: CFO


Peel Hunt LLP

James Steel                                                                                                              +44 (0)207 418 8900

Oliver Jackson


Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton




Notes to Editors


About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.


Further details can be found at: www.genedriveplc.com and www.genedrive.com


Back to previous page